Association between pretreatment emotional distress and immune checkpoint inhibitor response in non-small-cell lung cancer
Yue Zeng,Chun-Hong Hu,Yi-Zheng Li,Jian-Song Zhou,Shu-Xing Wang,Meng-Dong Liu,Zhen-Hua Qiu,Chao Deng,Fang Ma,Chun-Fang Xia,Fei Liang,Yu-Rong Peng,Ao-Xi Liang,Sheng-Hao Shi,Shi-Jiao Yao,Jun-Qi Liu,Wen-Jie Xiao,Xiao-Qiao Lin,Xin-Yu Tian,Ying-Zhe Zhang,Zhuo-Ying Tian,Ji-An Zou,Yun-Shu Li,Chao-Yue Xiao,Tian Xu,Xiao-Jie Zhang,Xiao-Ping Wang,Xian-Ling Liu,Fang Wu
DOI: https://doi.org/10.1038/s41591-024-02929-4
IF: 82.9
2024-05-14
Nature Medicine
Abstract:Emotional distress (ED), commonly characterized by symptoms of depression and/or anxiety, is prevalent in patients with cancer. Preclinical studies suggest that ED can impair antitumor immune responses, but few clinical studies have explored its relationship with response to immune checkpoint inhibitors (ICIs). Here we report results from cohort 1 of the prospective observational STRESS-LUNG study, which investigated the association between ED and clinical efficacy of first-line treatment of ICIs in patients with advanced non-small-cell lung cancer. ED was assessed by Patient Health Questionnaire-9 and Generalized Anxiety Disorder 7-item scale. The study included 227 patients with 111 (48.9%) exhibiting ED who presented depression (Patient Health Questionnaire-9 score ≥5) and/or anxiety (Generalized Anxiety Disorder 7-item score ≥5) symptoms at baseline. On the primary endpoint analysis, patients with baseline ED exhibited a significantly shorter median progression-free survival compared with those without ED (7.9 months versus 15.5 months, hazard ratio 1.73, 95% confidence interval 1.23 to 2.43, P = 0.002). On the secondary endpoint analysis, ED was associated with lower objective response rate (46.8% versus 62.1%, odds ratio 0.54, P = 0.022), reduced 2-year overall survival rate of 46.5% versus 64.9% (hazard ratio for death 1.82, 95% confidence interval 1.12 to 2.97, P = 0.016) and detriments in quality of life. The exploratory analysis indicated that the ED group showed elevated blood cortisol levels, which was associated with adverse survival outcomes. This study suggests that there is an association between ED and worse clinical outcomes in patients with advanced non-small-cell lung cancer treated with ICIs, highlighting the potential significance of addressing ED in cancer management. ClinicalTrials.gov registration: NCT05477979.
biochemistry & molecular biology,cell biology,medicine, research & experimental